Market Checkup: An In-Depth Look at Bristol-Myers Squibb

In this edition of The Motley Fool's health-care show Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at one of the largest pharmaceutical companies in the world: Bristol-Myers Squibb. This drugmaker posted results in line with analyst estimates last quarter, but what was behind it's massive year-over-year decline in revenue? What are the reasons to buy and sell this stock today? What should investors be watching in upcoming quarters? Watch today's show to find out what our analysts think.

One of the best parts of owning big pharma stocks like Bristol-Myers Squibb is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article Market Checkup: An In-Depth Look at Bristol-Myers Squibb originally appeared on

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story